Biomind Labs Inc.
BMND
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -529.13% | -226.45% | 83.86% | 94.28% | 85.07% |
| Total Depreciation and Amortization | -100.00% | -75.00% | -33.33% | 0.00% | -30.16% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 293.94% | 405.93% | -201.99% | -207.38% | -220.55% |
| Change in Net Operating Assets | 32.80% | 580.34% | 785.50% | 841.42% | 111.21% |
| Cash from Operations | 43.82% | 80.95% | 73.75% | 60.25% | 61.88% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -27.83% | -71.89% | -54.31% | -71.90% | -62.57% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 100.00% | -- | -- |
| Cash from Financing | -26.10% | -71.42% | -53.73% | -72.97% | -63.43% |
| Foreign Exchange rate Adjustments | -137.97% | -167.26% | -111.83% | 158.00% | -23.79% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -200.00% |
| Net Change in Cash | 130.82% | 99.59% | 122.39% | -19.57% | -242.77% |